On this page
Read the experiment
The finding and its boundary
The investigators reported improved fistula-healing measures during the animal follow-up. The work does not establish a replacement for human surgical assessment.
Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats.
- Experiment
- Experimental animal investigation with the intervention and outcomes specified in the indexed abstract.
- Study system
- Rats with surgically established rectovaginal fistulas
- Measured outcome
- Leakage, defects, histology, adhesions and obstruction
- Reported result
- The investigators reported improved fistula-healing measures during the animal follow-up.
- What this cannot establish
- The work does not establish a replacement for human surgical assessment.
What was actually tested
Rats with surgically established rectovaginal fistulas. The investigators measured leakage, defects, histology, adhesions and obstruction. The investigators reported improved fistula-healing measures during the animal follow-up.
The detail that changes the takeaway
An anatomical connection can have a specific clinical name without making a rodent experiment a patient trial. Etiology, infection, tissue quality and prior surgery may matter in people. The paper's artificial injury and controlled follow-up are only an early part of that larger question.
How far the result travels
The work does not establish a replacement for human surgical assessment.
A useful comparison
BPC-157 in a duodenum-to-skin fistula experiment examines leakage, healing and sphincter-pressure measurements. Here, the measured endpoint was leakage, defects, histology, adhesions and obstruction. Those outcomes belong to separate experiments; one is not a replication or a human confirmation of the other. Compare that distinction with the BPC-157 and an established fistula in rats: delayed treatment is still preclinical appraisal.
References & product documents
The evidence and service information used here.